高考英语时事热点话题阅读
热点07 新冠疫情相关的科研进展
一、阅读理解凸面镜应用
1
A doctor named Chepurnov from Siberia conducted a controversial coronavirus immunity test after surviving COVID-19 in March. The 68-year-old Russian doctor spent time with coronavirus-positive patients without wearing a mask to e if he could get a cond COVID-19 infection. The doctor was infected a cond time and experienced a wor COVID-19 ca than he had previously.幼儿园元宵节活动>山东省教育考试院
This unusual coronavirus immunity test can easily be filed under the “only in Russia” ction of COVID-19 news. Only in Russia was a coronavirus vaccine approved for mass u before any scientific rearch was shared with the world and before the drug cleared the Pha 3 trial. The story gets even crazier, considering the doctor’s age. At 68-years-old,
Alexander Chepurnov happens to be the kind of COVID-19 patient most at risk of developing a vere ca.
Even so, Chepurnov’s controversial experiment isn’t without worth. It’s certainly the kind of experiment that others wouldn’t necessarily approve of, especially in western countries. But it’s the kind of experiment that can yield results — and Chepurnov did get his wish. He was reinfected with COVID- 19 within six months from the first bout. Chepurnov and his rearch team started to monitor his antibodies. He discovered that they vanished after three months. “The obrvation showed a fairly rapid decrea,” he told the paper. “By the end of the third month from the start of the dia, they cead to be determined.” This falls in line with other studies about COVID-19 antibody life.
Chepurnov’s story also ems to fall in line with other studies that say immunity can last for at least 5-7 months. The story also proves that immunity lasts even after the antibodies are gone and suggests that other immune system components are indeed involved in providing prolonged protection. Others theorized that T cells would extend im
munity beyond the life of the first batch of antibodies. Chepurnov’s empirical findings are also important for vaccine rearch. If immunity lasts less than a year, more booster shots (加强针剂) might be needed after the initial dos.八卦阴阳
But Newsweek points out a problem with the experiment. Becau his first ca of COVID-19 hasn’t been diagnod via a PCR test. Also, Chepurnov’s experiment hasn’t been published in a scientific journal, and it’s unclear what scientific rigors were applied. Still, if his findings are accurate, Chepurnov is actually right to warn against using a herd immunity approach to beat the pandemic.
手机防水套
1. Why is Chepurnovs experiment considered controversial?
A. Its not effective. B. Its too dangerous.
C. Its disapproved of by Russia. D. Its not diagnod via a PCR test.
2. What does the underlined word "they" in Paragraph 3 probably refer to?
A. dias B. virus C. antibodies D. results
3. What is the finding of Chepurnovs experiment?
A. COVID-19 immunity lasts permanently in ones body.
B. The longevity of COVID-19 antibodies is about 3 months.鸡皮的营养价值
C. Old patients are most at risk of developing a vere COVID-19.
D. Vaccination can protect one from being infected with coronavirus.
4. Whats the main idea of the passage?
A. Siberia is a unique place for treating COVID-19 patients.
B. Newsweek found the evidence against herd immunity to COVID-19.
C. Rearches showed humans produce antibodies if infected with coronavirus.
狗狗可以吃什么D. A controversial experiment on coronavirus immunity was conducted in Russia.
2
Humans are no strangers to widespread virus,and each time a vaccine(疫苗）is developed, it gives us hope for the future. Now, the world is waiting for a vaccine to fight COVID-19.
Scientists worldwide have been rolling up their sleeves to work toward an effective novel coronavirus vaccine.
芦荟的资料Under the coordination(协调）of the World Health Organization (WHO),up to 172 countries have been engaging with the "largest and most diver COVID-19 vaccine portfolio",a plan known as the COVAX Global Vaccines Facility.
COVAX is a system for joint purchasing and balancing the risks of multiple vaccines. When a vaccine proves to be safe and effective, all countries within the facility will be able to access it, according to Xinhua.
The plan is aimed to ensure that all countries, no matter their economic status, can get the vaccine in a timely manner when one is available. It also makes sure that prices will be kept as low as possible.
＂A number of vaccines are now in the final stage of clinical trials," said WHO Director-General Tedros Adhanom Ghebreyesus on Aug 24,adding that the goal of COVAX is to deliver at least 2 billion dos of a vaccine by the end of 2021.
According to the WHO, at prent, nine potential vaccines are part of the portfolio.
To guarantee the equal access and fair assignment of COVID-19 vaccines,the WHO has said that the world needs to prevent vaccine nationalism-countries putting their own interests ahead of others in trying to cure supplies of a possible vaccine.
